Skip to main content
Premium Trial:

Request an Annual Quote

NHGRI Issues 10 RFAs to Fund Genome Sequencing Technology Development

NEW YORK (GenomeWeb News) - The National Human Genome Research Institute may fund approximately $24 million in fiscal year 2007 under requests for applications for 10 new and/or competing continuation grants for genome sequencing technologies.
 
There are five RFAs for near-term development of genome sequencing technologies, each with a different award mechanism, and five for genome sequencing technologies aimed at the $1,000 genome, also with several award mechanisms.
 
Both RFAs are modifications of RFAs announced in December 2005. The application deadlines are in late November 2007.
 
Near-Term Technology Development for Genome Sequencing
 
For the “Near-Term Technology Development for Genome Sequencing” RFAs, NHGRI expects to fund $12 million in awards, to be allocated as follows:
 
Under the R01 mechanism, NHGRI plans to make two to seven awards for a total of $4 million, subject to funding approval. Each project can apply for up to $1.5 million in direct costs per year. More information is available here.
 
Under the R21 mechanism, NHGRI may make five to nine awards for a total of $2 million. The direct costs are limited to $200,000 each year. More information is available here.
 
Under the R21/R33 mechanism, NHGRI will try to fund two to six awards for a total of $2 million. Direct costs are limited to no more than $200,000 per year for the R21 phase and no more than $1.5 million per year for the R33 phase. More information is available here.
 
Under the SBIR R43/R44 mechanism, NHGRI expects two to six awards for a total of $2 million. Each project will be restricted to $250,000 total costs per year and time periods up to 2 years may be requested for Phase I grants. For Phase II grants, the budgets are increased to $1.5 million total costs per year and time periods up to 3 years. More information is available here.
 
Under the STTR R41/R42 mechanism, NHGRI expects two to six awards for a total of $2 million. Each project will be restricted to $250,000 total costs per year and time periods up to 2 years may be requested for Phase I grants. For Phase II grants, the budgets are increased to $1.5 million total costs per year and time periods up to 3 years. More information is available here.
 
Revolutionary Genome Sequencing Technologies
 
For the “Revolutionary Genome Sequencing Technologies – The $1000 Genome” RFAs, NHGRI expects to fund $12 million in awards, subject to funding approvals, to be allocated as follows:
 
Under the R01 mechanism, NHGRI plans to make two to seven awards for a total of $4 million, subject to funding approval. Each project can apply for up to $1.5 million in direct costs per year. More information is available here.
 
Under the R21 mechanism, NHGRI may make five to nine awards for a total of $2 million. The direct costs are limited to $200,000 each year. More information is available here.
 
Under the R21/R33 mechanism, NHGRI will try to fund two to six awards for a total of $2 million. Direct costs are limited to no more than $200,000 per year for the R21 phase and no more than $1.5 million per year for the R33 phase. More information is available here.
 
Under the SBIR R43/R44 mechanism, NHGRI expects two to six awards for a total of $2 million. Each project will be restricted to $250,000 total costs per year and time periods up to 2 years may be requested for Phase I grants. For Phase II grants, the budgets are increased to $1.5 million total costs per year and time periods up to 3 years. More information is available here.
 
Under the STTR R41/R42 mechanism, NHGRI expects two to six awards for a total of $2 million. Each project will be restricted to $250,000 total costs per year and time periods up to 2 years may be requested for Phase I grants. For Phase II grants, the budgets are increased to $1.5 million total costs per year and time periods up to 3 years. More information is available here.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.